Cisema participated in the U.S. Commercial Service webinar on June 24, 2021, which provided an overview on China and Hong Kong’s rehabilitation healthcare market, market needs and sales opportunities, and explained how U.S. companies can enter these markets. Cisema experts Hamish King (COO) and Arthur Ng (BD North America) spoke about the regulatory requirements and registration pathway.
The webinar focused on China and Hong Kong’s rehabilitation equipment markets, both of which offer opportunities for foreign exporters. These markets are underdeveloped given current and future demand. The main sources of demand relate to postoperative rehabilitation of patients from the neurology, neurosurgery, orthopedics, pediatrics, gynecology and obstetrics, and cardiopulmonary departments.
China’s medical rehabilitation market is estimated to reach $14.4 billion in annual sales by 2023, with an annual compound growth rate of over 18 percent.
Upgrading China’s healthcare system is a government priority, spurred by population and healthcare realities. At the end of 2019, China registered 254 million people aged 60 and above, accounting for 18.1% of the total population. This demographic will reach 300 million by 2025. Chinese government data reveals 300 million patients with chronic disease and 30 million children aged 0-15 requiring rehabilitation. These realities drive the need for therapy equipment, daily living aids, mobility equipment, tele-rehabilitation services and body support devices.
• USCS China Market Introduction, Aliza Totayo, Commercial Officer, Global Market, ITA
• China and Hong Kong Rehabilitation Market Briefing by William Zhang, Partner, Pricewaterhouse Coopers Management Consulting
• Market Access Briefing – Regulatory Requirements and Registration Pathway by Cisema (Hamish King COO and Arthur Ng, BD North America)